Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Careers
  • Newsroom
Company Announcement
02 March 2021

Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand

Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading
Company Announcement
10 December 2020

Alvotech and Fuji Pharma Extend Biosimilar Partnership in Japan

Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates Alvotech and Japanese pharmaceutical company Fuji Pharma (Tokyo Stock Exchange: 4554) announce that they have agreed on an extension on their exclusive
Company Announcement
24 November 2020

Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical

Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China° Biosimilar candidates will be manufactured in a new Chinese biologic facility in Changchun Alvotech hf.
Company Announcement
19 November 2020

U.S. FDA and EMA have Accepted Regulatory Submissions for AVT02 - Alvotech

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and function The pharmacokinetic (PK) similarity study for AVT02 (AVT02-GL-101) has met its primary
Company Announcement
04 November 2020

Alvotech and Cipla Partner to Ensure Access to Biosimilars in South Africa

Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.
Company Announcement
27 October 2020

Alvotech Announces Private Placement Financing

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round. This has resulted in the company issuing new shares to a group of new investors and existing shareholders, which will further finance the development and release
Company Announcement
22 September 2020

Alvotech and DKSH Extend Partnership in Asia

Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing
Company Announcement
05 August 2020

Alvotech and Teva Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines
Company Announcement
12 May 2020

Alvotech Announces Positive Top-line Results for Two Comparative Studies.

Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary objectives The Phase 3 confirmatory efficacy and safety study for AVT02 (AVT02-GL-301) has met
Company Announcement
24 March 2020

Alvotech and DKSH Partner to Bring Key Biosimilar to Asia

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected APAC markets.
1…30313233
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.